Answers are grounded in this paper and cite their sources.
Aphidicolin, a potent DNA polymerase α inhibitor, has been explored in clinical trials for the treatment of cancer. So far, about 300 modified aphidicolins have been discovered. However, none have shown a stronger effect. Herein, we report 71 new (aphidicolins A1–A71, 1 – 71 ) and eight known ( 72 – 79 ) aphidicolin congeners from Botryotinia fuckeliana MCCC 3A00494, a fungus isolated from the western Pacific Ocean (−5572 m). The structures of 1 – 71 were determined through extensive spectroscopic analysis, X-ray crystallography, chemical derivatization, modified Mosher’s method, and the ECD exciton chirality method. Compounds 54 – 57 and 58 – 64 are novel 6/6/5/6/5 pentacyclic aphidicolins featuring tetrahydrofuran and dihydrofuran rings, respectively, while compounds 65 – 71 are rare noraphidicolins. Aphidicolin A8 ( 8 ) significantly induced apoptosis in T24 (IC 50 = 2.5 μM) and HL-60 (IC 50 = 6.1 μM) cancer cells by causing DNA damage. By docking its structure to the human DNA polymerase α binding pocket, 8 was found to form tight intermolecular contacts, elaborating aphidicolin A8 as a potently cytotoxic lead compound.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: